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Abstract. Blood-brain barrier (BBB) permeability is a recognized early feature of Alzheimer’s disease (AD). In the present
study, we examined consequences of increased BBB permeability on the development of AD-related pathology by tracking
selected leaked plasma components and their interactions with neurons in vivo and in vitro. Histological sections of cortical
regions of postmortem AD brains were immunostained to determine the distribution of amyloid-1-42 (A42), cathepsin
D, IgG, GluR2/3, and alpha7 nicotinic acetylcholine receptor (7nAChR). Results revealed that chronic IgG binding to
pyramidal neurons coincided with internalization of A42, IgG, GluR2/3, and 7nAChR as well as lysosomal compartment
expansion in these cells in regions of AD pathology. To test possible mechanistic interrelationships of these phenomena, we
exposed differentiated SH-SY5Y neuroblastoma cells to exogenous, soluble A42 peptide and serum from AD and control
subjects. The rate and extent of A42 internalization in these cells was enhanced by serum containing neuron-binding IgG
autoantibodies. This was confirmed by treating cells with individual antibodies specific for 7nAChR, purified IgG from AD
or non-AD sera, and sera devoid of IgG, in the presence of 100 nM A42. Initial co-localization of IgG, 7nAChR, and A42
was temporally and spatially linked to early endosomes (Rab11) and later to lysosomes (LAMP-1). A42 internalization was
attenuated by treatment with monovalent F(ab) antibody fragments generated from purified IgG from AD serum and then
1These authors contributed equally to this work.
∗Correspondence to: Robert G. Nagele, 2 Medical Center
Drive, Science Center, Room # 313A, Stratford, NJ 08084, USA.
Tel.: +1 856 566 6083; E-mail: nagelero@rowan.edu.
ISSN 1387-2877/20/$35.00 © 2020 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
346 E.L. Goldwaser et al. / Brain-Reactive IgG and Amyloid Deposition
rescued by coupling F(ab) fragments with divalent human anti-Fab. Overall, results suggest that cross-linking of neuron-
binding autoantibodies targeting cell surface proteins can accelerate intraneuronal A42 deposition in AD.
Keywords: A1-42, Alzheimer’s disease, autoantibodies, blood-brain barrier, brain-reactive autoantibodies, cerebrovascula-
ture
INTRODUCTION
Alzheimer’s disease (AD) is a devastating neu-
rodegenerative disease that currently carries with
it a forecast of ever-increasing prevalence and
debilitating social and economic costs to those
afflicted, caregivers, and their families. It is the
most common cause of dementia, now affect-
ing over 5 million people in the United States
[1]. Well-recognized hallmarks of AD pathology
include excessive amyloid- deposition intracellu-
larly (within neurons) and extracellularly as amyloid
plaques, tau hyperphosphorylation, formation of neu-
rofibrillary tangles, loss of synapses, and progressive
neurodegeneration with associated neuroinflamma-
tion [2–4]. The evolution of AD pathology can
span decades in patients and is thought to progress
unnoticed for 10–15 years before telltale symptoms
emerge and clinical detection becomes possible using
conventional means [5, 6]. Despite extensive research
over the past several decades, the factors, condi-
tions, and mechanisms that drive both the macro- and
microscopic pathological changes in the brain asso-
ciated with initiation and progression of this disease
remain unresolved.
Much work on postmortem AD brains, the brains
of numerous AD-relevant animal models, and cul-
tured cells has been directed toward understanding
how amyloid, primarily amyloid-1-42 (A42), is
deposited in the brain within neurons and amy-
loid plaques throughout AD pathogenesis [3, 7, 8].
Although plaque formation in human AD brains is
still generally considered an extracellular event, intra-
cellular A42 deposition has been reported as an
early pathological marker in AD brains, in the brains
of AD-relevant transgenic animal models, and in
various types of cultured neurons and neuron-like
cells [9–18]. A42 has been shown to bind with
high affinity to the alpha7 subtype of the nicotinic
acetylcholine receptor (7nAChR), which is abun-
dantly present on the surfaces of cholinergic and
cholinoceptive neurons (especially on cortical pyra-
midal cells) [9, 12, 19, 20]. Additionally, in an earlier
study, we showed that when 7nAChR-transfected
SK-N-MC neuroblastoma cells were exposed to sol-
uble, exogenous human A42 peptide, the resulting
7nAChR-A42 complexes were internalized and
accumulated within the lysosomal compartment [12,
20–22]. Also, treatment of adult mouse brain slice
cultures with human serum containing brain-reactive
autoantibodies or purified antibodies directed against
the 7nAChR was found to augment the rate and
extent of A42 accumulation selectively in pyramidal
neurons [23, 24]. The term “autoantibodies” is used
here to reflect the self-reactive property that these IgG
species exhibit.
Taken together, the above findings suggest that
access of neuron-binding autoantibodies and soluble
A42 peptide to the brain parenchyma, presumably
mediated by locally increased blood-brain barrier
(BBB) permeability, plays a key role in A deposi-
tion in the brain during AD pathogenesis. However,
details of the mechanisms driving this process are
lacking, as is the underlying reason for the appar-
ent requirement for advanced age. In the present
study, we examined the consequences of BBB func-
tional compromise on the development of AD-related
pathology by examining and tracking the fate of
selected leaked plasma components and their inter-
actions with neurons in vivo and in vitro. Results
show that, in postmortem AD brain, chronic autoan-
tibody binding was associated with internalization
of key neuronal cell surface proteins, GluR2/3 and
7nAChR, and coincident with lysosomal compart-
ment expansion. To determine if these observations in
AD brains are mechanistically linked, we investigated
the effects of exposure of differentiated SH-SY5Y
human neuroblastoma cells to exogenous, soluble
A42 and serum from AD and control subjects. The
rate and extent of A42 internalization was enhanced
by both AD and control sera. In addition, treatment
of cells with antibodies specific to 7nAChR or puri-
fied IgG obtained from either AD or non-AD controls
showed similar enhancement of A42 internaliza-
tion. We also found that initial co-localization of
IgG, 7nAChR, and A42 was temporally and spa-
tially related to the early endosomal marker, Rab11,
and to the lysosomal marker, LAMP-1, at later time
points. Lastly, A42 and antibody internalization
was attenuated by treatment with monovalent F(ab)
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antibody fragments generated from IgG purified from
AD patient sera, and was rescued by crosslink-
ing F(ab) with anti-F(ab) antibodies, suggesting that
cross-linking of bivalent neuron-binding autoanti-




Brain tissue from patients with sporadic AD
(n = 23, age-range = 71–88) and age-matched,
neurologically normal individuals (n = 14, age-
range = 69–83) were obtained from the Harvard
Brain Tissue Resource Center (Belmont, MA), the
Cooperative Human Tissue Network (Philadelphia,
PA), and the UCLA Tissue Resource Center (Los
Angeles, CA). Postmortem intervals were <24 h
and pathological confirmation of AD was according
to criteria defined by the National Institute on
Aging and the Reagan Institute Working Group
on Diagnostic Criteria from the Neuropathological
Assessment of AD [25]. Formalin-fixed tissues
were processed for routine paraffin embedding and
sectioning according to established protocols (see
below). Control tissues exhibited minimal localized
microscopic AD-like neuropathology.
Immunohistochemistry (IHC)
IHC was used to investigate the expression and
localization of selected proteins in the human
brain samples as described previously [23]. Briefly,
paraffin-embedded human tissues were deparaf-
finized using xylene and rehydrated through a
graded series of decreasing concentrations of ethanol.
Antigenicity was enhanced by microwaving sec-
tions in citrate buffer. Endogenous peroxidase was
quenched by treating sections with 3% H2O2
for 10 min. Sections were incubated in blocking
serum and then treated with primary antibodies
at appropriate dilutions for 1 h at room tempera-
ture. After a thorough rinse in PBS, corresponding
biotin-labeled secondary antibody was applied for
30 min at room temperature. Sections were treated
with avidin-peroxidase complex (Vectastain ABC
Elite, Vector Laboratories, Inc., Foster City, CA)
and visualized with 3-3-diaminobenzidine-4-HCL
(DAB)/H2O2 (Imm-Pact-DAB) (Vector). They were
then lightly counterstained with hematoxylin, dehy-
drated through increasing concentrations of ethanol,
cleared in xylene, and mounted in Permount. To
detect endogenous IgG, anti-human IgG (Vector
Laboratories, Inc., Foster City, CA) was used as
the primary antibody with no secondary antibody
treatment. Controls consisted of brain sections
treated with non-immune serum or omission of
the primary antibody. Specimens were examined
and photographed with a Nikon FXA microscope
and digital images were recorded using a Nikon
DXM1200F digital camera and analyzed using
NIS-Elements Imaging Software (Nikon Instru-
ments Inc. USA) and Cell Profiler image analysis
software.
Cell culture
An in vitro model was developed using differenti-
ated human neuroblastoma SH-SY5Y cells (ATCC
CRL-2266). Cells were first grown in 10% fetal
bovine serum (FBS; Sigma F6178) in Dulbecco’s
Minimal Essential Medium (DMEM; Gibco)/F12
(Cellgro; Invitrogen, UK) media until 80% con-
fluence in 35 mm glass-bottom dishes. Cells were
then differentiated using 10 M retinoic acid and
0.2% FBS in DMEM/F12 media for three days.
Differentiating cells sprout neuron-like processes
that establish connections with cells in the vicin-
ity and were used for experimentation at roughly
70% confluence. Cells were treated with 100 nM
HiLyteTM fluor 488 (FITC)-labeled A42 (a phys-
iologically relevant concentration) with or without
selected sera for time points ranging from 30 min
to 72 h. Selected sera used were obtained from a
young non-demented control (YC) subject, an old-
aged non-demented control (OC) subject, and an
Alzheimer’s disease patient (AD), and were diluted
1:50 in serum-free media [26]. The AD, YC, and OC
sera (one from each group) used for these in vitro
studies were selected after analyzing and compar-
ing their autoantibody profiles using immunoblotting
and Human Protein Microarrays as described previ-
ously [26–31]. In these previous studies, we have
analyzed the IgG autoantibody signatures of over
100 AD sera and a similar number of control (young
and old) sera. Based on these profiles, we selected
a single sample from each subject group that best
reflected the group. Approval to use these sera
was obtained from the University of Medicine and
Dentistry-Stratford (now Rowan University) Institu-
tional Review Board. Human sera were heated to
56◦C for 25 min to inactivate complement for certain
experiments.
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Immunocytochemistry (ICC)
Differentiated SH-SY5Y cells were washed in
cation-free 1x Hank’s Balanced Salt Solution (HBSS,
without calcium or magnesium; Invitrogen, UK)
three times prior to experimental protocol, and later
were fixed in 4% paraformaldehyde (PFA). If the cell
surface membrane was to be stripped so as to not
include surface-bound, non-internalized peptide for
A42 internalization assays, immediately prior to fix-
ation, three acid washes (0.1 M Glycine, pH 2.5) of
2 min each were performed, followed by two more
HBSS washes to remove any residual acid. After
fixation, cells were treated with 3% BSA in PBS
with Tween (PBS-T) (for removal of cell surface
membranes) or PBS alone (for intact cell surface
membrane assays) and then probed with primary
antibody overnight at 4◦C followed by secondary
antibodies for 1 h at room temperature. For detection
of serum IgG bound to SH-SY5Y cells, anti-human
IgG conjugated to an Alexa-fluor 594 (Cy3) fluo-
rophore was used as secondary antibody. Nuclei were
counterstained with Hoechst. Confocal microscopy
(Nikon) and epifluorescence optics were used to cap-
ture images, and NIS-Elements software was used to
perform image analysis and quantification of signal
intensities.
Peptides and antibodies
For IHC, anti-A42 antibodies were obtained from
Millipore International (Temecula, CA) (polyclonal,
Cat. No. AB5078 P, dilution 1:50) and Pharmingen
(San Diego, CA) (polyclonal Cat. No. 4767, dilution
1:50); biotinylated anti-human IgG antibodies were
obtained from Vector Laboratories (Burlingame,
CA) (host: goat, Cat. No. PK-6103 and BA-3000,
dilution 1:100); mouse anti-GluR2 was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA)
(polyclonal N19, SC-7611) and Zymed Laborato-
ries (Cat. No. 32-0300); Cathepsin D was obtained
from Upstate Biotechnology (Lake Placid, NY)
(Cat. No 06-467).
For ICC experiments, exogenous A42 (beta-
amyloid 1–42, HiLyteTM fluor 488 (FITC); AnaSpec,
Inc., San Jose, CA, USA; AS-60479-01) was used
for internalization assays. A42 monomers were pre-
pared by reconstituting 0.1 mg lyophilized powder
in 50 l of 1% NaOH. Samples were diluted to
1 mg/ml in PBS and stored at –20◦C in 5 l aliquots.
Cells were treated with 100 nM A42 in serum-free
medium prepared immediately prior to use. Medium
was added to peptide-treated cells to avoid binding
in serum prior to administration. Fresh aliquots were
used for each experiment to avoid repeated freeze-
thaw cycles that could trigger potential aggregate
formation and precipitation/fibrillization. Human
serum samples were obtained from Analytical Bio-
logical Services Inc. (Wilmington, DE). Samples
were numerically coded and included the following
information: age, gender, the presence or absence
of a detectable neurological disease, an indication
of disease severity via a Mini-Mental Status Exam
score (MMSE), and postmortem interval. Use of these
samples was approved by the UMDNJ-Stratford IRB
(now Rowan University).
Primary antibodies for ICC included: anti-synaptic
vesicle (SV) 2 (Developmental Studies Hybridoma
Bank, dilution 1:1000); anti-Tau6 (Sigma, St. Louis,
MO, USA; Cat. No. T8201, dilution 1:500); anti-
LAMP1 (Sigma, St. Louis, MO, USA; Cat. No.
L1418, dilution 1:200); anti-Rab-11 (Sigma, St.
Louis, MO, USA, Cat. No. R5903, diluted 1:100);
anti-7nAChR (Sigma, St. Louis, MO, USA, Cat.
No. M220, diluted 1:500). Human serum used as
a primary antibody was diluted 1:50. Anti-rabbit
secondary IgG Cy3 (1:1500 dilution), anti-mouse
IgG-488 (1:500 dilution), and goat anti-human
AlexaFluor-488 (1:500 dilution) were used as sec-
ondary antibodies.
IgG purification and F(ab) monovalent antibody
preparation
The IgG fraction from sera was purified using
spin-column chromatography (Pierce Melon Gel IgG
Purification Kit) according to manufacturer’s proto-
col and confirmed using SDS-PAGE and absorption
at 280 nm (data not shown). F(ab) fragments were
prepared from purified IgG using a Fab preparation
kit (Pierce Protein Research Products; ThermoFisher
Scientific). Briefly, purified IgG was digested for
4–6 h at 37◦C with 1% (w/w) papain at pH 7.0
with 0.01 M cysteine. F(ab) fragments were iso-
lated using filtered chromatography as per the
manufacturer’s instructions. The purity of F(ab)
fragments was confirmed using spectrophotometry
at 280 nm.
Image analysis
Image analysis for ICC experiments was car-
ried out using a Nikon Confocal microscope and
NIS-Elements software. The software was used to
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delineate cells manually as a region of interest (ROI)
at 20x by selecting 10 random images on an exper-
imental dish where only entire cells were seen and
counted. This roughly accounted for eight cells per
image, and ten images per experiment, performed in
triplicate, reaching about 240 cells per experiment
for analysis. Fluorescence signal intensity emanat-
ing from FITC-labeled A42 within the ROI was
calculated. After exporting data to an Excel spread-
sheet, the summed signal intensity for FITC-A42
was divided by the total area of the ROI to deter-
mine the signal intensity (FITC-A42) per unit area
of the cells. To measure internalized FITC-A42, sur-
face membranes were first removed using a 0.1 M
glycine acid wash prior to image acquisition as
described above. To retain surface bound FITC-A42,
no acid wash or detergents were included in the
protocol.
Statistics
Experiments were run in triplicate and image
analysis was blinded to limit bias. Statistical signif-
icance of differences between treatment groups was
evaluated using the two-tailed Student’s t-test, with
levels of significance indicated as follows: *p < 0.05;
**p < 0.01; ***p < 0.001. Variation within each treat-
ment group was represented by standard deviation
from the mean (SEM). Image acquisition parameters
were determined by the user and kept identical within
a given experiment.
RESULTS
In neurons of AD brains, exogenous Aβ42 and
IgG are internalized along with key cell surface
proteins and deposited within the lysosomal
compartment
Previous IHC studies of human AD brains and
some AD-relevant transgenic mouse models have
shown that deposition of A peptides, especially
A42, occurs preferentially within the lysosomal
compartment of specific neuronal subtypes, espe-
cially pyramidal cells, and in amyloid plaques in
a number of different brain regions [9, 12, 23, 24,
26, 30, 33] (Fig. 1A–C). Histological sections of
AD brains also reveal that, under conditions of BBB
compromise, immunoglobulins (Igs) leak into the
parenchyma of AD brains and exhibit preferential
affinity for the same pyramidal neurons that con-
tain A42 as well as extracellular amyloid plaques
(Fig. 1D). Co-localization of IgG and A42 has been
demonstrated in cerebral cortex and hippocampus
of AD brains in our previous study [23], as well
as in the cerebral cortex of diabetic and hyperc-
holesterolemic pigs [33]. IHC also showed intense
7nAChR-positive immunostaining in pyramidal
cells and throughout dense-core amyloid plaques,
supporting the possibility that at least some plaques
are derived from the death and lysis of local Ig-
and A42-overburdened neurons (Fig. 1E). A simi-
lar localization pattern was seen in pyramidal cells
for GluR2/3 (Fig. 1F).
Serum IgG autoantibodies bind to differentiated
SH-SY5Y cells
Differentiated SH-SY5Y human neuroblastoma
cells were selected as a model system to study the cel-
lular response to conditions thought to approximate
those in brain tissue during early stages of AD patho-
genesis in the context of increased BBB permeability.
SH-SY5Y cells were first induced to differentiate by
treatment with 10 M retinoic acid (RA) for 72 h, a
response highlighted by changes in cell shape to one
that more resembles neurons, including extension of
neurite-like processes (Figs. 2A–D, 3A, B). Immuno-
cytochemistry and confocal microscopy confirmed
that differentiation of SH-SY5Y cells was accom-
panied by increased expression of neuronal proteins
consistent with neuronal differentiation, including
7nAChR (Fig. 2A), synaptic vesicle 2a (SV2;
Fig. 2B), microtubule-associated protein-2 (Map2;
Fig. 2C), and Tau6 (Fig. 2D). These proteins are nat-
urally expressed in this cell type, thus reinforcing
their suitability as a neuronal model. Differentiated
cells also showed markedly increased reactivity to
IgG antibodies present in human serum compared to
undifferentiated cells (Fig. 3A–C). Cells not treated
with serum as controls (Ctrl) showed lower signals
(Fig. 3C). Interestingly, addition of serum from an
AD patient did not significantly increase the extent
of IgG antibody binding to SH-SY5Y cells over
that from a non-demented age-matched older control
(OC) individual or sera from a younger non-demented
control individual (YC) (Fig. 3C). This suggests that
all human sera may contain brain-reactive autoanti-
bodies, regardless of age or the presence or absence
of disease, as was shown in our previous study using
western blot analysis [31] and immunohistochem-
istry [23, 31, 33].
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Fig. 1. In neurons of AD brains, exogenous A42 and IgG are internalized along with key cell surface proteins and deposited within the
lysosomal compartment. A) IHC of a histological section of cerebral cortex of AD brain showing deposition of A42 in amyloid plaques
(APs) and in pyramidal cells (PCs). B, C) Cathepsin D (CathD) immunostaining reveals a great expansion of the lysosomal compartment
in PCs in AD brains over that of controls. D) Section of AD brain showing preferential affinity of IgG for certain PCs and APs, along with
adjacent non-reactive, IgG immuno-negative cells. E) IHC shows intense 7nAChR-positive immunostaining in PCs, and 7nAChR was
also detected throughout dense-core APs, supporting the possibility that at least some APs are derived from the death and lysis of local
Ig- and A42-overburdened PCs. F) A similar localization pattern was seen in PCs for GluR2/3, a surface receptor found with intracellular
distribution, in the vicinity of the cerebrovasculature. Red arrows, A42-burdened neurons. Red arrowheads, IgG immuno-negative cells.
Scale bar = 20 m.
Internalization of exogenous Aβ42 is enhanced
by brain-reactive autoantibodies
We next investigated the effects of serum autoan-
tibodies on the rate and extent of internalization
of exogenous soluble A42 in differentiated SH-
SY5Y cells. Exposure of cells to a physiologically
relevant dose (100 nM) of FITC-labeled A42 in
medium without serum (controls) resulted in detec-
tion of some A42 along neurites and within small,
uniformly sized granules that tended to cluster pref-
erentially on one side of the nucleus within 3 h
(Fig. 4A). At 72 h, many smaller granules contain-
ing FITC-labeled A42 were aggregated into larger
structures in the cytoplasm, but a significant amount
of FITC-labeled A42 remained restricted to smaller
granules located primarily along the cell perimeter,
suggesting that this A42 may be bound to the out-
side of the cell surface membrane and aggregated into
“patches” that have not yet entered the cell (Fig. 4B).
Addition of human AD serum (final dilution = 1 : 50)
to the culture medium significantly increased the rate
and extent of intracellular FITC-A42 accumulation
and aggregation over that of cells treated with FITC-
A42 alone for 72 h (Fig. 4C). As in AD brains, there
was a clear tendency for internalized A42 to coalesce
into large aggregates in close proximity to the nucleus
(cf. Fig 1A), with very little FITC-A42 remaining
associated with the cell surface membrane (Fig. 4C).
Surprisingly, quantitative comparison of the effects
of sera from an AD patient, an age-matched non-
demented subject (OC), and a younger non-demented
control (YC) individual revealed no significant dif-
ferences in the extent of A42 accumulation at 72 h
(Fig. 4D). This increased internalization of FITC-
A42 over controls lacking serum was attributed to
the IgG fraction of serum since cells treated with IgG
purified from AD serum showed levels of intracel-
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Fig. 2. Differentiated SH-SY5Y cells are a useful model system to
study mechanisms associated with neuronal A42 internalization.
SH-SY5Y cells differentiated by treatment with retinoic acid for
72-h. A-D) Differentiation was confirmed by changes in cell shape,
extension of neuritic processes, and detection of robust expression
of the following neuronal markers of differentiation using ICC:
(A) 7nAChR; (B) synaptic vesicle 2a (SV2); (C) microtubule-
associated protein 2 (Map-2); and (D) tau6. Scale bar = 5 m.
lular A42 accumulation comparable to cells treated
with whole serum (Fig. 4D).
Internalization of exogenous Aβ42 can be
enhanced by autoantibodies directed against a
single abundant neuronal surface protein (NSP)
To determine if IgG autoantibodies against a single
common and abundant neuronal cell surface protein
can influence the rate and extent of exogenous A42
internalization in neurons, we treated differentiated
SH-SY5Ycells with 100 nM FITC-labeled A42 for
72 h in medium containing antibody directed against
the 7nAChR (diluted 1:500). Fig. 5A shows that, at
72 h, FITC-A42 (green) and cy3-labeled 7nAChR
(red) were co-localized as complexes (yellow) that
were internalized and trafficked together intra-
cellularly. Treatment of cells with anti-7nAChR
antibodies significantly increased A42 accumula-
tion over that of cells exposed to FITC-A42 only
(Fig. 5B). However, the amount of internalized FITC-
A42 in anti-7nAChR-treated cells was less than
that in cells treated with purified IgG obtained from
AD serum (Fig. 5B). To confirm that binding of
IgG autoantibodies is responsible for enhanced FITC-
A42 internalization in differentiated SH-SY5Ycells,
depletion of IgG from AD serum resulted in a
dramatic reduction of the amount of intracellular
FITC-A42 to levels below that of cells treated with
FITC-A42 only (Fig. 5B). The observation that cells
treated with FITC-A42 alone showed higher levels
of internalized FITC-A42 than those treated with the
same concentration of FITC-A42 in IgG-depleted
serum is not unexpected. Human serum comprises of
a number of both well-characterized and uncharacter-
ized biomolecules. IgG depleted serum still contains
serum components that can compete for the same
binding sites on cell surfaces. Also, it has been shown
that some serum components have affinity for A42.
By removing IgG from the serum, it enhances the
ability of other serum components to compete for
binding sites on the neuronal cell surface. Secondly,
the removal of serum IgG may allow other serum
components to form complexes with FITC-A42 with
varying (including higher) affinities than in their
native states.
Autoantibody-mediated augmentation of Aβ42
internalization requires an antibody
cross-linking step
We have proposed that extensive crosslinking of
antigen targets present on neuronal cell surfaces
by bivalent autoantibodies triggers endocytosis, a
phenomenon that could conceivably provide much
of the driving force for intraneuronal accumulation
of exogenous A42 as well as chronic depletion
of other key proteins and receptors from cell sur-
face membranes in vivo. To test this possibility,
we compared the effects of bivalent versus mono-
valent antibodies on the rate and extent of A42
internalization. Purified monovalent antibody [F(ab)]
fragments, capable of binding but not crosslinking
antigens on cell surfaces, were prepared by enzymatic
cleavage of IgG antibodies isolated from human AD
serum. Differentiated SH-SY5Y cells treated with
medium containing 100 nM FITC-labeled A42 plus
monovalent F(ab) fragments showed reduced A42
internalization and accumulation (Fig. 6). Addition
of anti-F(ab) antibodies to medium containing mono-
valent F(ab) fragments rescued the cross-linking
function and increased intracellular A42 to lev-
els comparable to that in cells treated with AD
patient serum and IgG purified from AD patient
serum (Fig. 6). Lastly, treatment of cells with heat-
inactivated (HI) serum caused a modest reduction
in A42 internalization, suggesting that comple-
ment binding does not make a major contribution
to the observed A42 internalization events medi-
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Fig. 3. Differentiated SH-SY5Y cells show increased reactivity to IgG autoantibodies present in human serum. A, B) Confocal images
of non-differentiated (A) and differentiated (B) SH-SY5Y cells treated with human serum (diluted 1:50) in medium for 24 h and then
immunostained with Cy3-labeled (red) anti-human IgG antibodies and counterstained with Hoechst stain (blue) to highlight nuclei. C)
Differentiated cells show increased binding of serum IgG over that of non-differentiated cells. Unexpectedly, the extent of IgG binding in
cells treated with serum from an AD patient did not differ significantly from an older non-demented subject or younger control. Controls
(Ctrl) were performed with omission of serum and addition of secondary antibody. Scale bar = 10 m. ***p < 0.001. AD, Alzheimer’s disease
serum; OC, old-aged matched, non-demented control; YC, younger, non-demented control.
ated by serum IgG (Fig. 6). This finding confirms
that crosslinking of IgG antibodies bound to target
antigens on neuronal cell surfaces enhances A42
internalization via endocytosis.
Serum-derived IgG and Aβ42 are internalized via
endocytosis and target the lysosomal
compartment
Previous studies have shown that, in human AD
brains, chronic endocytosis leads to targeting and
expansion of the lysosomal compartment of neurons
to the point where it eventually occupies a substan-
tial fraction of total cytoplasmic volume (cf. Fig. 1B).
To examine and confirm the key steps of this pro-
cess using our in vitro model system, SH-SY5Y cells
were treated from 3 to 72 h with FITC-A42 with or
without AD serum. Immunocytochemistry was used
to detect Rab-11 (an early endosome marker) and
LAMP-1 (a late endosome/early lysosome marker),
and co-localization of these with FITC-A42 was
detected by superposition of red and green sig-
nals to yield yellow fluorescence (Fig. 7). At 3-h
time points, essentially all internalized FITC-A42
was contained within early endosomes, as shown
by its co-localization with Rab11 (Fig. 7A); none
was associated with lysosomes at this early time
point (Fig. 7B). In cells treated for 3 h and 72 h
with FITC-A42 in the presence of serum from an
AD patient, co-localization of A42 and IgG was
evident (Fig. 7C, F), although, as expected, internal-
ization of IgG also occurred independently of A42.
At 72 h, little or no co-localization of A42 with
Rab-11 was detected (Fig. 7D), but significant accu-
mulations of co-localized A42 and LAMP-1 were
observed (Fig. 7E).
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Fig. 4. Internalization of exogenous A42 is enhanced by binding of IgG autoantibodies. A, B) Differentiated SH-SY5Y cells treated
with a physiologically relevant dose (100 nM) of FITC-labeled A42 for 3 and 72 h in medium without human serum showing that A42
internalization can occur in the absence of serum. A) At 3 h, FITC-A42 was localized to small, dispersed and uniformly sized granules.
B) As is typically seen in A42-overburdened neurons in regions with AD pathology, a significant fraction of internalized A42 was
concentrated within aggregates at 72 h. C) Addition of AD serum to media containing 100 nM FITC-A42 increased the rate and extent of
A42 internalization with very little detected on the cell surface. D) Quantification of the effects of different human sera on the rate and extent
of FITC-A42 internalization after 72 h of treatment. Exposure of differentiated SH-SY5Y cells to 100 nM FITC-labeled A42 in media
without serum (controls) resulted in detection of a relatively low level of intracellular A42. Addition of human serum to the media greatly
increased the rate and extent of FITC-labeled A42 internalization observed at 72 h. Comparison of the effects of serum from an AD patient,
an age-matched non-demented subject, and a younger non-demented control individual revealed no significant differences in the amount of
A42 accumulation over 72 h, and intracellular A42 levels in these groups were all significantly higher than in cells treated with A42 alone.
In addition, IgG purified from AD serum showed comparable A42 internalization rates to that of whole serum, suggesting that, among
serum components, IgG is largely responsible for the observed A42 internalization in SH-SY5Y cells. Scale bar = 10 m. ***p < 0.001. AD,
Alzheimer’s disease serum; OC, old-aged matched, non-demented control; YC, young-aged, non-demented control; ADpurIgG, purified
IgG from AD sera; white arrow, newly internalized/plasma-membrane bound A42; yellow arrow, aggregates of A42-containing granules.
DISCUSSION
In AD patients, A42 peptide progressively accu-
mulates in the brain and is localized preferentially in
the walls of blood vessels, amyloid plaques (APs),
and the perikaryon of pyramidal neurons, especially
cholinergic or cholinoceptive neurons [3, 34]. The
source of the A42 that deposits in AD brains remains
unknown and controversial. Studies on postmortem
AD brain tissue and the brains of transgenic mouse
models exhibiting neuronal overexpression of the
amyloid- protein precursor and other AD-relevant
proteins have failed to provide a clear answer to
the fundamental question of how A peptides are
deposited within neurons and amyloid plaques dur-
ing AD pathogenesis. In the context of increased
blood-brain barrier (BBB) permeability, a continual
supply of exogenous, soluble, blood-borne A pep-
tides, including A42, can enter into the brain tissue
along with other plasma components. This A42 has
been shown to be capable of binding to 7nAChRs
on the surfaces of cholinoceptive neurons with high
affinity [12, 22]. It also binds to many other pro-
teins (albeit with lower affinities) found elsewhere
in the blood and brain. Under conditions of BBB
leak, the influx of vascular A42 into the brain leads
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Fig. 5. A42 internalization is enhanced by anti-7nAChR autoantibodies. Differentiated cell treated with 100 nM FITC-labeled (green)
A42 for 72 h in medium containing antibody directed against the 7nAChR and visualized using Cy3 (red) secondary antibodies. FITC-
A42 internalization was enhanced over that in cells treated with FITC-A42 alone, and nearly all was co-localized with 7nAChR (yellow)
either in small dispersed granules or uniform clusters of these granules. A) Cell treated for 72 h in medium containing both FITC-A42 and
serum from an AD patient showing extensive FITC-A42 internalization and co-localization with 7nAChR. B) Quantification showing
increased A42 internalization in cells treated with anti-7nAChR antibody over those exposed to FITC-A42 alone. Cells treated with IgG
purified from AD serum showed a higher level of FITC-A42 internalization than those treated with anti-7nAChR. Removal of IgG from
AD serum caused a dramatic reduction in A42 internalization. Scale bar = 10 m. *p < 0.05, ***p < 0.001. AD, Alzheimer’s disease serum.
to the formation of A42-7nAChR complexes on
neuronal cell surfaces, which are subsequently inter-
nalized, presumably via endocytosis, and accumulate
readily within the lysosomal compartment of these
cells [35, 36]. Mechanisms driving internalization of
A42 and intraneuronal accumulation remain poorly
understood.
Our previous studies on the brains of AD and
age-matched, non-demented control subjects have
shown that a compromised BBB also allows serum
immunoglobulins (Igs), especially IgG, to enter the
brain parenchyma and interact with the surfaces
of neurons. Some of these IgGs can react with
brain proteins expressed on the neuronal surfaces
(neuron-binding or brain-reactive autoantibodies).
The pathophysiological consequences of this bind-
ing are largely unknown [3, 9, 21, 22]. In the
present study, we investigated this process using
differentiated SH-SY5Y human neuroblastoma cells
which, like many neurons in the brain, express
7nAChRs on their surfaces. These cells were
used to test the hypothesis that, under conditions
of BBB compromise where plasma components
including antibodies and soluble A42 chroni-
cally leak into the brain parenchyma, brain-reactive
autoantibodies common in the blood can bind selec-
tively to exposed cell surfaces of neurons that
express their cognate antigen targets. Further, we
sought to test whether autoantibody-mediated cross-
linking of surface antigens, via induced endocytosis,
drives internalization of cell surface-bound A42-
7nAChR complexes and thereby facilitates gradual
accumulation of A42 in the neuron lysosomal
compartment.
The results of the present study highlight the poten-
tially important role of blood-borne, brain-reactive
autoantibodies in the pathogenesis of AD. This study
reports the following major findings. First, expo-
sure of differentiated SH-SY5Y neuroblastoma cells,
which express the 7nAChR, to exogenous, solu-
ble A42 and human serum revealed that the rate
and extent of A42 internalization and accumula-
tion in these cells were increased in the presence of
serum, regardless of age or whether the serum was
from an AD or non-demented (control) subject. Sec-
ond, this effect was mediated by IgG autoantibodies
present in serum, since depletion of IgG from serum
reduced the rate and extent of intraneuronal A42
accumulation, whereas treatment with purified IgG
enhanced it to levels comparable to that of whole
serum. Third, we show that treatment of cells with
autoantibodies directed against a single, well-known,
abundant cell surface receptor (e.g., the 7nAChR,
which is also capable of high-affinity binding to
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Fig. 6. A42 internalization is driven primarily by IgG cross-
linking on neuronal surfaces. Cells were first treated with
FITC-A42 to establish a baseline level of A42 internalization
in the absence of other factors. A42 was then co-administered
with AD serum, purified IgG from AD sera, heat-inactivated (HI)
AD sera (to disable binding of complement protein), monovalent
F(ab) IgG fragments or monovalent F(ab) fragments co-treated
with anti-F(ab) fragment secondary antibody (aFab). The latter was
used to restore bivalency and thereby autoantibody cross-linking.
In cells treated with monovalent F(ab) fragments (incapable of
cross-linking) in conjunction with FITC-A42, A42 internal-
ization was reduced compared to those treated with AD serum,
purified IgG from AD serum or heat-inactivated serum. However,
when media containing monovalent F(ab) fragments was supple-
mented with antibodies directed against F(ab) fragments to restore
cross-linking abilities, the A42 internalization rate was increased
to a level comparable to that of purified IgG from AD serum. Fab,
monovalent F(ab) fragment; aFab, anti-F(ab) fragment secondary
antibody; AD, Alzheimer’s disease sera; AD purIgG, IgG purified
from AD sera; HI, heat-inactivated; ns, non-significant; **p < 0.01;
***p < 0.001.
A42) increases the rate and extent of neuronal inter-
nalization of exogenous soluble A42. Fourth, both
A42 and autoantibody internalization were reduced
by treatment of cells with monovalent F(ab) anti-
body fragments generated from IgG purified from AD
patient serum, and was rescued by crosslinking these
F(ab) fragments with anti-F(ab) antibodies. These
observations suggest that cross-linking of bivalent,
neuron-binding autoantibodies accelerates intraneu-
ronal A42 deposition, presumably via endocytosis.
Finally, we show that trafficking of internalized A42
appears to be similar to that in AD brains, with initial
co-localization of IgG, 7nAChR, and A42 in dif-
ferentiated SH-SY5Y cells temporally and spatially
related to the early endosome marker protein, Rab11,
and at later time points to the lysosomal marker,
LAMP-1.
Internalization and accumulation of exogenous
Aβ42 is enhanced by brain-reactive
autoantibodies commonly found in the blood
Recent studies using human protein microarrays
have revealed the presence of thousands of different
autoantibodies in human sera, irrespective of disease
status, suggesting a homeostatic role [26, 37]. Not
surprisingly, these studies have revealed that many
of these autoantibodies show cross-species reactivity,
suggesting affinity for similar, conserved epitopes as
we have seen in immunohistochemical preparations
of human, rodent and pig brain [23, 31, 33]. The fact
that certain specific autoantibodies show increased
production in response to the presence of disease,
however, favors the idea that one important func-
tion of these autoantibodies is the removal of the
debris that has entered into the general circulation.
This property has led us to explore the potential of
some autoantibodies as blood-based biomarkers for
use in detecting specific diseases [26, 28–30, 38].
A limitation of the present study is that only a sin-
gle serum sample was selected for use from each
group. In our previous studies, over 100 AD and
healthy controls from various ages were analyzed for
autoantibody profiles using protein microarrays. This
work revealed that the presence of many thousands
of IgG autoantibodies in the blood is ubiquitous.
Here, as a proof of concept, we chose a represen-
tative serum sample from each demographic group
to test the potential pathogenic role of autoantibod-
ies in intracellular deposition of A42 peptide. It is
well known that, in brain regions exhibiting AD-
related pathological changes, loss of synapses and
death of the associated neurons is pervasive [39, 40].
This kind of neurodegeneration results in a continual
release of neuronal debris into the brain interstitial
space, which subsequently makes its way into the
cerebrospinal fluid and, finally, the peripheral circu-
lation. We believe that the presence of this debris in
the peripheral circulation triggers increased produc-
tion of debris-specific autoantibodies, including those
directed against key, abundant cell surface targets that
are critical for proper neuronal function [41]. Further,
we have proposed that, in the context of BBB com-
promise, some autoantibodies with cognate targets on
neuronal surfaces can bind to these surfaces and elicit
a sequence of events that contributes to AD pathol-
ogy and plays a role in neuronal A42 deposition
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Fig. 7. A42 is trafficked through endosomes (Rab11) to the lysosome compartment (LAMP-1) following internalization. SH-SY5Y treated
from 3 to 72 h with FITC-A42 with or without AD serum. ICC was used to detect Rab-11 (early endosomes) and LAMP-1 (late endo-
somes/early lysosome marker). Co-localization was detected by superposition of red and green signals to yield yellow fluorescence. At
3 h, nearly all internalized FITC A42 was associated with early endosomes (Rab-11). In cells treated for 3 h and 72 h with FITC A42
in the presence of serum from an AD patient, co-localization of A42 and IgG was evident, although some internalization of A42 also
occurred independently of IgG. At 72 h, little or no co-localization of A42 with Rab11 was detected, but significant accumulations of co-
localized A42 and LAMP-1 (lysosomes) were common. Rab-11, early endosome; LAMP-1, lysosomal marker; AD, Alzheimer’s disease
human serum; green arrow, A42; red arrow, secondary protein of interest; yellow arrow, co-localization; **p < 0.01; ***p < 0.001; Scale
bar = 10 m.
and perhaps the downstream formation of amyloid
plaques.
In the present study, we used differentiated SH-
SY5Y neuroblastoma cells as a model system to test
the above scenario. Surprisingly, IgG autoantibodies
from AD serum showed a similar level of binding to
cells as did serum from a non-demented, age-matched
control subject and a younger subject. This finding,
in parallel with our previous studies, raises the pos-
sibility that all human sera contain brain-reactive
(including neuron-binding) autoantibodies, regard-
less of age or the presence of disease, and that these
autoantibodies are present in the general circulation
prior to initiation of AD-related pathology. Our previ-
ous studies that have used human protein microarrays
to examine autoantibody profiles across a wide range
of ages support this idea and have shown that com-
plex autoantibody profiles that include thousands of
autoantibodies are commonly (perhaps ubiquitously)
expressed in the blood in individuals of all ages
[26]. It also suggests that increased BBB permeabil-
ity may be an important disease trigger that elicits
a cascade of events beginning with the binding of
autoantibodies to their neuronal cell surface targets.
We also found that binding of serum autoantibod-
ies to SH-SY5Y cells increased the rate and extent
of internalization of exogenous soluble A42 added
to the culture medium in a physiologically relevant
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Fig. 8. Interaction of extravasated BrABs with NSPs triggers endocytosis and results in intraneuronal accumulation of A42 and depletion
of NSPs from cell surfaces. Under conditions of BBB compromise, blood-borne A42 and brain-reactive autoantibodies flood into the
brain parenchyma. Some interact with cognate neuronal surface proteins (including receptors; NSPs), while A42 binds to 7nAChRs with
picomolar affinity. Bivalent autoantibodies cross-link their targets on neuronal surfaces, which can trigger endocytosis and internalization
of cross-linked NSPs and surface-bound A42-7nAChR complexes. Within the acidic environment of endosomes and lysosomes, A42
forms aggregates which are non-degradable and tend to accumulate. Over time, chronic leak of autoantibodies into the brain tissue results
in continual internalization of A42 within neurons, which interferes with their proper functioning and leads to failure to maintain their
dendritic trees and associated synapses. Death and lysis of these A42-overburdened neurons contributes to the formation of amyloid plaques
(APs). This cell death is also a source of neuronal debris that finds its way into cerebrospinal fluid and, via arachnoid villi, into the general
circulation, where it triggers an immune response leading to production of autoantibodies directed against such neuronal debris. Under
conditions of increased BBB permeability, these are able to access cell surface-bound targets in the brain and thus perpetuate the engine that
drives the observed pathology.
dose (100 nM), as determined previously [3]. A42
was initially observed within small, uniformly sized
granules in neurites and in the perinuclear cytoplasm,
but these later were concentrated within larger jux-
tanuclear clusters. Interestingly, as was seen for IgG
binding, quantitative comparison of the effects of sera
from an AD patient, an age-matched non-demented
subject, and a younger non-demented control individ-
ual revealed no significant differences in the extent
of A42 accumulation at 72 h. This finding suggests
that neuron-binding autoantibodies are present in the
blood regardless of the presence or absence of dis-
ease. Furthermore, this effect was largely attributed
to the IgG fraction of the blood since cells treated
with IgG purified from AD serum showed levels
of intracellular A42 accumulation comparable to
the cells treated with whole serum, and depletion
of IgG from serum markedly reduced A42 accu-
mulation. It was interesting to see that the amount
of A42 accumulation was higher in cells treated
with FITC-A42 alone than in cells treated with
the same concentration of FITC-A42 plus serum
that was depleted of IgG. We attribute this reduc-
tion in FITC-A42 internalization in the group treated
with IgG-depleted AD serum to the fact that FITC-
A42 has to compete with an increased number of
non-specific, transitory cell surface binding events
due to the higher level of serum proteins and other
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components which are absent in the FITC-A42
only group.
Neuronal internalization of exogenous Aβ42 is
enhanced by autoantibodies directed against a
single abundant neuronal surface protein
Previous studies have suggested that A42 binds
to 7nAChR with picomolar affinity [42] and that
this binding on the surfaces of 7nAChR-expressing
neurons in AD brains leads to internalization
of the resulting A42-7nAChR complexes and
their accumulation within the lysosomal compart-
ment as confirmed using immunohistochemistry [9,
12, 13]. Here, we show that IgG autoantibodies
present in the blood can augment this process. The
selectivity of IgG autoantibodies for certain types
of neurons, especially pyramidal neurons, is evi-
dent and reflected by the differential pattern of
immunoreactivity amongst neurons with virtually
identical exposures to the same nearby leaking
vessel. For example, immunohistochemistry fre-
quently shows intensely immunoreactive neurons
interspersed among completely immuno-negative
neurons in the same sections. This observation, which
has been documented in human, rodent, and pig
brains as well as in organotypic brain slice cultures
derived from adult mice, is difficult to explain based
on a Fc-mediated IgG binding mechanism via Fc
receptors [23, 31, 33]. Similarly, our observations
on the rescue of crosslinking of Fab fragments with
anti-Fab antibodies also argues against an Fc-receptor
binding mechanism. In this case, Fc fragments of the
anti-Fab antibodies bound to Fab fragments would
be expected to be oriented away from the plasma
membrane of these cells.
In the present study, we also tested the possi-
bility that an IgG autoantibody directed against a
single abundant neuronal surface protein, in this case
the 7nAChR, can influence the rate and extent of
exogenous A42 internalization in neurons. Results
showed that treatment of cells with anti-7nAChR
antibodies significantly increased A42 accumula-
tion over that of cells exposed to A42 alone. In
addition, A42 and 7nAChR were internalized and
trafficked together to the lysosomal compartment as
in neurons of AD brains. This shows that autoanti-
bodies directed against a single, relatively abundant
cell surface protein are capable of driving A42 accu-
mulation, with the expectation that the potency of this
effect would be dependent on the titer of the specific
neuron-binding autoantibody as well as the relative
abundance of the receptor or target protein on the cell
surface. Of course, the presence of multiple autoan-
tibodies to cell surface proteins would, accordingly,
be expected to magnify this effect, thereby increasing
the rate of A42 deposition as well as precipitating
synaptic and neuronal loss.
Our results also provide explanation for selective
vulnerability of cholinergic and cholinoceptive neu-
rons to A42 deposition in AD brains. The strong
binding affinity of A42 to 7nAChR in neurons that
express this receptor may selectively enhance A42
accumulation in these cells, which helps to explain
why cholinergic tone is diminished in the early phases
of AD and, similarly, why anticholinesterases pro-
vide modest and short-lived benefits only at this mild
stage. The accumulation of A42 may trigger vari-
ous neurodegenerative changes, including interfering
with the ability of neurons to support their exten-
sive dendrite trees and axonal projections, and may
ultimately contribute to more widespread neuronal
loss and aberrant circuitry and connectivity patterns
as the disease progresses. Of course, many differ-
ent autoantibodies may be able to bind to neurons
with and without 7nAChRs. However, the reduced
affinity of A42 for the surfaces of cells lacking this
receptor suggests that these cells would experience
little or no A42 accumulation at this concentration
compared to cells that express 7nAChR. It is rea-
sonable to suggest, however, that at later stages of the
disease, when amyloid-burdened cells and BBB dam-
age are more rampant and widespread, A42 levels
are high enough to accumulate appreciably in other
cell types throughout the brain. Moreover, we would
like to emphasize that the chronic interaction between
other autoantibodies and neuronal surface proteins
may initiate a more general loss of these proteins due
to receptor-mediated endocytosis, a loss that could
lead to cognitive changes as a cumulative result of
neuronal functional deficits that expand into networks
that span cortical and subcortical regions.
Autoantibody-mediated augmentation of Aβ42
internalization requires an antibody
cross-linking step
We have proposed that extensive cross-linking
of antigen targets present on neuronal surfaces by
bivalent brain-reactive autoantibodies triggers endo-
cytosis and internalization of autoantibody-target
protein complexes. Chronic receptor stripping via
endocytosis could contribute to intraneuronal accu-
mulation of exogenous A42 and depletion of key
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proteins and receptors from cell surface membranes.
To test this, we compared the effects of biva-
lent and purified monovalent autoantibodies, both
derived from human serum, on the rate and extent
of A42 internalization. We found that differenti-
ated SH-SY5Y cells treated with monovalent F(ab)
fragments exhibited reduced exogenous A42 inter-
nalization and accumulation. We were able to rescue
the native cross-linking function by addition of anti-
F(ab) antibodies to medium containing monovalent
F(ab) fragments, which restored the rate and extent
of intracellular A42 accumulation to levels compa-
rable to that of cells treated with AD patient serum
and IgG purified from AD patient serum. This phe-
nomenon has been linked to the pathophysiology of
other antibody-mediated neuropsychiatric disorders,
including N-methyl D-aspartate receptor encephali-
tis [43]. Although IgG was the only antibody species
under investigation in the present study, there is a
growing literature to suggest that other less abun-
dant isotypes, including IgM and IgA, may also
share a role in the pathophysiology in question,
which is an active area of research across neu-
ropsychiatry and psychoneuroimmunology. IgG may
not be unique in its ability to induce cross-linking
and A42 internalization and, with future studies,
it may be revealed that all autoantibodies are capa-
ble of similarly contributing to the amyloidogenic
burden of neurons. Furthermore, we propose that
this mechanism of neurodegeneration, initiated by
increased local BBB permeability, may be appli-
cable to other parts of the brain, with the type of
symptoms dictated by the brain region and con-
nectivity affected [43, 44]. It is important to note,
however, that other mechanisms of cellular uptake
are likely at play in A42 internalization, includ-
ing caveolin-, clathrin-, and phagocytosis-mediated
mechanisms, which were not explored in the present
study.
Conclusion
In conclusion, these results are consistent with
the notion that, in the context of increased BBB
permeability, chronic binding of brain-reactive
autoantibodies to abundant cell surface protein tar-
gets and the resulting antibody-mediated endocytosis
may be a major pathway for early pathogenic neu-
ronal deposition of soluble A42 originating from
the blood in AD brains. This mechanism could also
account for the depletion of key cell surface pro-
teins leading to the observed neuronal dysfunction
and loss of synapses associated with early AD-related
neuropathology.
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